Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B known ✓ | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C known ✓ | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.58 |
| ▸ | PDE5A | O76074 | 2/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | PDE1A | P54750 | 1/20 | 0.58 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.58 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7794732 | 0.92 | PDE4A (0.49) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL149749 | 0.92 | PDE4A (0.57) | PDE5APDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL28844121 | 0.91 | PDE4A (0.57) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7796197 | 0.88 | PDE4A (0.44) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7794556 | 0.87 | ALDH1A1 (0.46) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29801535 | 0.85 | LTB4R (0.43) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27379808 | 0.84 | LTB4R (0.43) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5958056 | 0.81 | PDE4A (0.51) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7796503 | 0.81 | PDE4A (0.53) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8863081 | 0.79 | PDE4A (0.51) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | claimed |
| CN-114929233-A | Phosphodiesterase type V inhibitor compositions, methods of making them, and methods of using them | 美国瑞根特有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-0754069-B1 | TREATMENT OF PULMONARY VASOCONSTRICTION AND ASTHMA | GEN HOSPITAL CORP (US) | 2004-06-23 | — | — | EP | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-4058026-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM | American Regent, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114929233-A | Phosphodiesterase type V inhibitor compositions, methods of making them, and methods of using them | 美国瑞根特有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021096871-A3 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM | AMERICAN REGENT, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021096871-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2011-07-14 | — | — | US | disclosed |
| US-20080032933-A1 | Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070042957-A1 | TYPE V PHOSPHODIESTERASE INHIBITORS AND NATRIURETIC POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | VIVUS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | PDE4A 6/4885PDE4B 10/4885PDE4C 8/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE4A 106/4885PDE4B 122/4885PDE4C 95/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE4A 5/4885PDE4B 8/4885PDE4C 7/4885 |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | PDE3A, PDE3B, PDE12 | PDE4A 6/4885PDE4B 10/4885PDE4C 8/4885 |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | PDE4A 6/4885PDE4B 10/4885PDE4C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.